

CITATION REPORT

List of articles citing

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

DOI: 10.1097/01.smj.0000208120.73327.db
Southern Medical Journal, 2006, 99, 257-73.

Source: <https://exaly.com/paper-pdf/39995351/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
238	Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. 2006 , 5, 20		55
237	Lipid-lowering effects of colestevlam HCl in combination with ezetimibe. 2006 , 22, 2191-200		55
236	Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. 2006 , 15, 1337-51		21
235	Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. 2006 , 3, 664-72		15
234	Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. 2007 , 18, 289-97		42
233	The use of colestevlam hydrochloride in the treatment of dyslipidemia: a review. 2007 , 8, 2569-78		28
232	Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colestevlam HCl in patients with type 2 diabetes mellitus. 2007 , 23, 1673-84		35
231	Bile acid sequestrants and the treatment of type 2 diabetes mellitus. 2007 , 67, 1383-92		130
230	Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation. 2008 , 10, 1004-11		15
229	The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorption. 2008 , 2, S20-S28		20
228	Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. 2008 , 198, 77-84		24
227	Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. 2008 , 83, 333-42		37
226	Colestevlam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. 2008 , 24, 995-1009		36
225	Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. 2008 , 295, G813-22		47
224	Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. 2008 , 24, 2189-202		10
223	Colestevlam hydrochloride: a specifically engineered bile acid sequestrant. 2008 , 3, 237-255		13
222	More choices than ever before: emerging therapies for type 2 diabetes. 2008 , 34, 518-34		27

221	Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. 2008 , 283, 3694-701	45
220	Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. 2008 , 52, 136-44	61
219	Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. 2008 , 23, 502-11	36
218	Bile acid sequestrants as a therapeutic option for glucose lowering in type 2 diabetes mellitus. <i>Endocrine Practice</i> , 2008 , 14, 644-7	3.2 5
217	Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. 2009 , 32 Suppl 2, S237-45	211
216	Update on patented cholesterol absorption inhibitors. 2009 , 19, 1083-107	6
215	Farnesoid X receptor as a therapeutic target for dyslipidemia. 2009 , 4, 587-594	2
214	Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. 2009 , 31, 245-59	17
213	Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. 2009 , 31, 2549-58	55
212	Antioxidant and bile acid binding activity of buckwheat protein in vitro digests. 2009 , 57, 4372-80	62
211	Role of bile acids and bile acid receptors in metabolic regulation. 2009 , 89, 147-91	1093
210	Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. 2009 , 38, 79-97	73
209	Pharmacotherapy of hyperglycemia. 2009 , 10, 2415-32	11
208	Protocolo de tratamiento de las dislipidemias aterogénicas. 2009 , 10, 2737-2741	
207	Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. 2009 , 6, 475-487	1
206	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. 2010 , 5, 825-834	1
205	Bile acid sequestrants for lipid and glucose control. 2010 , 10, 70-7	54
204	Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. 2010 , 51, 806-16	73

203	Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. 2010 , 52, 1455-64		140
202	Chemical composition of Atlantic spider crab <i>Maja brachydactyla</i> : Human health implications. 2010 , 23, 230-237		51
201	Comparing apples and pears: assessment of lipid-lowering therapies differentiated by side effects. 2010 , 64, 1324-6		
200	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. 2010 , 12, 384-92		106
199	Abstracts of the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. April 21-25, 2010. Boston, Massachusetts, USA. <i>Endocrine Practice</i> , 2010 , 16 Suppl 2, 1-49	3.2	1
198	The role of bile acid sequestrants in the management of type 2 diabetes mellitus. 2010 , 8 Suppl 1, S15-21		4
197	Bile salts and obesity. 2010 , 47, 395-6		0
196	Bile acid sequestrants: glucose-lowering mechanisms. 2010 , 8 Suppl 1, S3-8		20
195	Combination drug-diet therapies for dyslipidemia. 2010 , 155, 220-7		7
194	Pharmacologically-induced metabolic acidosis: a review. 2010 , 33, 371-91		31
193	Utilization of lipid lowering medications among adults in the United States 1999-2006. 2010 , 208, 456-60		27
192	A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. 2010 , 10, 305-14		17
191	A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. 2011 , 5, 76-81		34
190	Ezetimibe--a new approach in hypercholesterolemia management. 2011 , 63, 1335-48		30
189	Introducci3n. 2011 , 23, 1-2		1
188	Efectos hipoglucemiantes de las resinas de intercambio. Del secuestro de los 3cidos biliares a la activaci3n del metabolismo de la glucosa. 2011 , 23, 3-8		
187	Tratamiento de la hipercolesterolemia y prevenci3n de las enfermedades cardiovasculares mediante la inhibici3n de la reabsorci3n de 3cidos biliares con resincolestiramina. 2011 , 23, 9-16		1
186	Combination therapy for dyslipidemia. 2011 , 26, 420-3		6

185	Cholesterol-lowering activity of the major polyphenols in grape seed. 2011 , 16, 5054-61		112
184	Colesevelam for type 2 diabetes mellitus. 2011 ,		
183	Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. 2011 , 13, 137-43		24
182	Overcoming obstacles in risk factor management in type 2 diabetes mellitus. 2011 , 13, 613-20		17
181	Emerging options in the treatment of dyslipidemias: a bright future?. 2011 , 16, 247-70		13
180	Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. 2011 , 7, 137-44		5
179	Safety review of combination drugs for hyperlipidemia. 2011 , 10, 363-71		14
178	In vitro binding capacity of bile acids by defatted corn protein hydrolysate. 2011 , 12, 1066-80		28
177	Polysome profiling in liver identifies dynamic regulation of endoplasmic reticulum translatoe by obesity and fasting. 2012 , 8, e1002902		39
176	Bile acid sequestrants: more than simple resins. 2012 , 23, 43-55		60
175	Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. <i>Journal of Lipid Research</i> , 2012 , 53, 1723-37	6.3	202
174	Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. 2012 , 8, 515-25		13
173	Delineation of biochemical, molecular, and physiological changes accompanying bile acid pool size restoration in Cyp7a1(-/-) mice fed low levels of cholic acid. 2012 , 303, G263-74		14
172	Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins. 2012 , 49, 1-17		12
171	Inhibition of cholesterol absorption: targeting the intestine. 2012 , 29, 3235-50		14
170	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. <i>Endocrine Practice</i> , 2012 , 18 Suppl 1, 1-78	3.2	312
169	Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?. 2012 , 5, 43-54		2
168	Documento Abordaje de la dislipidemia. Sociedad Española de Arteriosclerosis (parte II). 2012 , 24, 40-52		3

167	Preventive aspects in peripheral artery disease. 2012 , 6, 53-70	6
166	Colesevelam for type 2 diabetes mellitus. 2012 , 12, CD009361	14
165	Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012 , 5, 125-34	6
164	Assessment of cholesterol absorption inhibitors nanostructured aluminosilicate and cholestyramine using in vitro lipolysis model. 2012 , 101, 291-300	11
163	Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. 2012 , 55, 432-42	115
162	Intolerance to statins: mechanisms and management. 2013 , 36 Suppl 2, S325-30	98
161	Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO. 2013 , 78, 137-46	14
160	Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity. 2013 , 228, 117-23	15
159	Bile acid receptors in non-alcoholic fatty liver disease. 2013 , 86, 1517-24	91
158	Polymeric bile acid sequestrants Synthesis using conventional methods and new approaches based on controlled/living radical polymerization. 2013 , 38, 445-461	29
157	Cultivar variations in antioxidant and antihyperlipidemic properties of pomelo pulp (<i>Citrus grandis</i> [L.] Osbeck) in Thailand. 2013 , 139, 735-43	56
156	Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. 2013 , 304, G371-80	109
155	Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations. 2013 , 20, 57-60	5
154	Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. 2013 , 24, 227-32	25
153	Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr $-/-$ mice versus hamsters. <i>Journal of Lipid Research</i> , 2013 , 54, 1283-99	6.3 27
152	Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. 2013 , 11, 152-6	12
151	The anti-hypercholesterolemic effect of low p53 expression protects vascular endothelial function in mice. 2014 , 9, e92394	2
150	Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. 2014 , 171, R47-65	49

149	Are add-on agents to statin therapy necessary in hypercholesterolemia?. 2014 , 9, 695-707	
148	Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. 2014 , 31, 683-94	3
147	Cardiometabolic impact of non-statin lipid lowering therapies. 2014 , 16, 390	5
146	Bile metabolism and lithogenesis. 2014 , 94, 361-75	23
145	Bile acids, obesity, and the metabolic syndrome. 2014 , 28, 573-83	99
144	Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. 2014 , 28, 361-77	29
143	Safety and efficacy of colesevelam HCl in the treatment of elderly patients. 2014 , 31, 461-70	5
142	Bile acid-controlled transgene expression in mammalian cells and mice. 2014 , 21, 81-90	19
141	Antidyslipidemic effects of a farnesoid X receptor antagonist in primates. 2014 , 106, 25-31	8
140	Synthetic therapeutic gene circuits in mammalian cells. 2014 , 588, 2537-44	52
139	Hypolipidemic Effect and Mechanism of Palmatine from <i>Coptis chinensis</i> in Hamsters Fed High-Fat diet. 2015 , 29, 668-73	30
138	Bile Acid Sequestrants: Risk Benefits and Role in Treating Dyslipidemias. 2015 , 453-463	1
137	Bile acid elevation after Roux-en-Y gastric bypass is associated with cardio-protective effect in Zucker Diabetic Fatty rats. 2015 , 24, 70-4	6
136	Potential role of bioactive compounds of <i>Phaseolus vulgaris</i> L. on lipid-lowering mechanisms. 2015 , 76, 92-104	35
135	Pharmacologic management of types 1 and 2 diabetes mellitus and their complications in women of childbearing age. 2015 , 35, 158-74	3
134	Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. 2015 , 11, 523-32	15
133	Role of Lipocalin-type prostaglandin D2 synthase (L-PGDS) and its metabolite, prostaglandin D2, in preterm birth. 2015 , 118-119, 28-33	5
132	Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. 2015 , 9, 295-304	90

131	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. 2015 , 8, 618-27		41
130	Outcomes from treating bile acid malabsorption using a multidisciplinary approach. 2015 , 23, 2881-90		19
129	Medical Management of Serum Lipids and Coronary Heart Disease. 2015 , 39-55		
128	Familial hypercholesterolemia. 2015 , 33, 169-79		47
127	Innovative therapies in diabetes: colesevelam and bromocriptine. 2015 , 758-764		
126	Polymeric drugs: Advances in the development of pharmacologically active polymers. 2015 , 219, 369-382		56
125	Towards the design of hypolipidaemic peptides: Deoxycholate binding affinity of hydrophobic peptide aggregates of casein plastein. <i>Journal of Functional Foods</i> , 2015 , 18, 129-136	5.1	22
124	Hypolipidemic activity of common (<i>Fagopyrum esculentum</i> Moench) and tartary (<i>Fagopyrum tataricum</i> Gaertn.) buckwheat. 2015 , 95, 1963-7		19
123	Effects of extraction solvents of dietary plants on lipid lowering activity. 2016 , 10, 538-545		
122	IFN- β secretion in gut of Ob/Ob mice after vertical sleeve gastrectomy and its function in weight loss mechanism. 2016 , 36, 377-382		2
121	Hipercolesterolemia familiar: artículo de revisión. 2016 , 23, 4-26		2
120	Synthesis of tailor-made bile acid sequestrants by supplemental activator and reducing agent atom transfer radical polymerization. 2016 , 6, 52143-52153		9
119	Identification of liver CYP51 as a gene responsive to circulating cholesterol in a hamster model. 2016 , 5, e16		3
118	Hypolipidemic and Antihyperlipidemic Drugs. 2016 , 285-315		2
117	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. 2016 , 118, 19A-32A		7
116	inhibits the absorption and synthesis of cholesterol. 2016 , 5, 301-308		10
115	Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. 2016 , 14, 237		69
114	Alginate-based encapsulation of polyphenols from <i>Clitoria ternatea</i> petal flower extract enhances stability and biological activity under simulated gastrointestinal conditions. 2016 , 61, 772-779		79

113	Novel bile acid sequestrant: A biodegradable hydrogel based on amphiphilic allylamine copolymer. 2016 , 304, 493-502		12
112	Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease. 2016 , 50, 119-35		2
111	Invited review: Growth-promoting effects of colostrum in calves based on interaction with intestinal cell surface receptors and receptor-like transporters. 2016 , 99, 4111-4123		34
110	Familial Hypercholesterolemia. 2016 , 45, 1-16		7
109	Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. 2016 , 104, 9-21		130
108	The Cholesterol-Lowering Effects of Probiotic Bacteria on Lipid Metabolism. 2016 , 699-722		3
107	Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids. 2017 , 27, 826-836		25
106	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. <i>Endocrine Practice</i> , 2017 , 23, 1-87	3.2	535
105	Regulation of Energy Homeostasis After Gastric Bypass Surgery. 2017 , 19, 459-484		5
104	Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowering effect of Si-miao-yong-an decoction: Application of LC-MS/MS method to determine 6 major bile acids in rat liver and plasma. 2017 , 135, 167-175		17
103	Bioactive Plant Molecules, Sources and Mechanism of Action in the Treatment of Cardiovascular Disease. 2017 , 315-336		16
102	Endogenous Cholesterol Excretion Is Negatively Associated With Carotid Intima-Media Thickness in Humans. 2017 , 37, 2364-2369		10
101	In Vitro Bile Acid Binding Capacities of Red Leaf Lettuce and Cruciferous Vegetables. 2017 , 65, 8054-8062		15
100	Increasing the Bile Acid Sequestration Performance of Cationic Hydrogels by Using an Advanced/Controlled Polymerization Technique. 2017 , 34, 1934-1943		3
99	Bark Extracts of Ceylon Cinnamon Possess Antilipidemic Activities and Bind Bile Acids In Vitro. 2017 , 2017, 7347219		10
98	Bile acid sequestrants for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. 2017 ,		0
97	Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice. 2017 , 16, 145		29
96	The Role of the Gut Microbiota in Bile Acid Metabolism. 2017 , 16, s15-s20		70

95	Cowpea: an overview on its nutritional facts and health benefits. 2018 , 98, 4793-4806		80
94	Diet1, bile acid diarrhea, and FGF15/19: mouse model and human genetic variants. <i>Journal of Lipid Research</i> , 2018 , 59, 429-438	6.3	19
93	Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. 2018 , 27, 656-665		8
92	Polymeric bile acid sequestrants: Review of design, in vitro binding activities, and hypocholesterolemic effects. 2018 , 144, 300-317		17
91	Microbiome modulates intestinal homeostasis against inflammatory diseases. 2018 , 205, 97-105		17
90	Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. 2018 , 7, 212562		5
89	Bile acids and their effects on diabetes. 2018 , 12, 608-623		22
88	Lipid management in patients with chronic kidney disease. 2018 , 14, 727-749		82
87	Preclinical discovery and development of colesivelam for the treatment of type 2 diabetes. 2018 , 13, 1161-1167		5
86	Isolation and identification by high resolution liquid chromatography tandem mass spectrometry of novel peptides with multifunctional lipid-lowering capacity. 2018 , 111, 77-86		19
85	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. 2018 , 104, 269-281		1
84	Structural Basis of Bioactivity of Food Peptides in Promoting Metabolic Health. 2018 , 84, 145-181		12
83	Idiosyncratic Adverse Drug Reactions. 2018 , 681-716		3
82	Animal models to study bile acid metabolism. 2019 , 1865, 895-911		60
81	New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs. 2019 , 104, 2463-2472		10
80	Therapeutic targets of hypercholesterolemia: HMGCR and LDLR. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 1543-1553	3.4	15
79	Cyanidin-3-rutinoside acts as a natural inhibitor of intestinal lipid digestion and absorption. 2019 , 19, 242		13
78	Pathophysiology, Differential Diagnosis, and Treatment of Diabetic Diarrhea. 2019 , 64, 3385-3393		7

77	Hypolipidemic and Antioxidant Activities of in Diabetic Rats. 2019 , 17, 47-51		2
76	Akebia Saponin D Regulates the Metabolome and Intestinal Microbiota in High Fat Diet-Induced Hyperlipidemic Rats. 2019 , 24,		10
75	n-3 Fatty Acids Abrogate Dyslipidemia-Induced Changes in Bile Acid Uptake, Synthesis, and Transport in Young and Aged Dyslipidemic Rats. 2019 , 54, 39-51		3
74	Bile acids and the metabolic syndrome. 2019 , 56, 326-337		25
73	Koumiss consumption modulates gut microbiota, increases plasma high density cholesterol, decreases immunoglobulin G and albumin. <i>Journal of Functional Foods</i> , 2019 , 52, 469-478	5.1	17
72	Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. 2019 , 73, 65-91		98
71	Anthocyanin extracts of lingonberry (<i>Vaccinium vitis-idaea</i> L.) attenuate serum lipids and cholesterol metabolism in HCD-induced hypercholesterolaemic male mice. 2019 , 54, 1576-1587		5
70	Gluc-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. 2020 , 105,		5
69	Prebiotic role of softwood hemicellulose in healthy mice model. <i>Journal of Functional Foods</i> , 2020 , 64, 103688	5.1	11
68	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. 2020 , 64, e2000480		2
67	Ability of chicken protein hydrolysate to lower serum cholesterol through its bile acid binding activity. 2020 , 18, 493-499		1
66	Identification of Peptides Potentially Responsible for Hypolipidemic Activity of a Hydrolysate from Olive Seeds. 2020 , 68, 4237-4244		4
65	Withaferin-A down-regulate enterohepatic circulation of bile acids: An insight from a hyperlipidemic rat model. 2020 , 2, 100035		
64	TMT-based proteomics analysis reveals the efficacy of jiangzhuo formula in improving the lipid profiles of dyslipidemia rats. 2021 , 264, 113390		3
63	Pharmacological and Metabolic Significance of Bile Acids in Retinal Diseases. 2021 , 11,		2
62	Untargeted fecal metabolomics revealed biochemical mechanisms of the blood lipid-lowering effect of koumiss treatment in patients with hyperlipidemia. <i>Journal of Functional Foods</i> , 2021 , 78, 104355 ^{5.1}		2
61	Robust and Comprehensive Targeted Metabolomics Method for Quantification of 50 Different Primary, Secondary, and Sulfated Bile Acids in Multiple Biological Species (Human, Monkey, Rabbit, Dog, and Rat) and Matrices (Plasma and Urine) Using Liquid Chromatography High Resolution Mass Spectrometry (LC-HRMS) Analysis. 2021 , 32, 2033-2049		1
60	Bile acid sequestrants: a review of mechanism and design. 2021 , 73, 855-861		0

59	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. 2021 , 21, 815-834	4
58	lipid-lowering properties of the fruits of two [(L.) Spreng] cultivars as affected by maturity stage and thermal processing.. 2021 , 2, 100020	
57	Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia. 2021 , 11, 634780	9
56	The Interdependency and Co-Regulation of the Vitamin D and Cholesterol Metabolism. 2021 , 10,	4
55	Bile salts adsorption on dextran-based hydrogels. 2021 , 190, 270-283	1
54	Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis. 2021 , 28, 550-568	8
53	DYSLIPIDEMIAS. 2009 , 303-320	1
52	Bile Acid Sequestrants. 2009 , 281-287	3
51	LDL-cholesterol: The lower the better. 2019 , 31 Suppl 2, 16-27	6
50	Disturbances in Microbial and Metabolic Communication across the Gut-Liver Axis Induced by a Dioxin-like Pollutant: An Integrated Metagenomics and Metabolomics Analysis. 2021 , 55, 529-537	10
49	Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. 2015 , 125, 386-402	385
48	The relationships of markers of cholesterol homeostasis with carotid intima-media thickness. 2010 , 5, e13467	32
47	Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. 2011 , 6, e24564	15
46	Grape Seed Procyanidins and Cholestyramine Differentially Alter Bile Acid and Cholesterol Homeostatic Gene Expression in Mouse Intestine and Liver. 2016 , 11, e0154305	17
45	Anti-obesity Potential of Selected Tropical Plants via Pancreatic Lipase Inhibition. 2017 , 6,	6
44	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. 2020 , 27, 1021-1040	10
43	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. 2019 , 25, 4063-4084	65
42	Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR- α agonist treatment. 2011 , 60, 627-36	48

41	The effect of colestevlam treatment on bile acid and lipid metabolism and glycemic control in healthy men. 2016 , 65, 995-1003		4
40	Mechanisms of triglyceride metabolism in patients with bile acid diarrhea. 2016 , 22, 6757-63		8
39	Biological Effect of on Kidney Status of Hypercholesterolemic Rats. 2017 , 13, S430-S436		5
38	An Integrated Bile Acids Profile Determination by UHPLC-MS/MS to Identify the Effect of Bile Acids Supplement in High Plant Protein Diet on Common Carp (). <i>Foods</i> , 2021 , 10,	4.9	0
37	Drug Treatment. 2008 , 131-159		
36	Improving glycemic and cholesterol control through an integrated approach incorporating colestevlam - a clinical perspective. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009 , 2, 11-21	3.4	2
35	Dyslipidemia: Pathogenesis and Management. 2010 , 435-456		
34	Targeting Multiple Risk Factors to Reduce Complications of Type 2 Diabetes: Treatment Imperatives. <i>Endocrine Practice</i> , 2010 , 16, 21-26		3.2
33	Disorders of Lipid Metabolism. 2011 , 1633-1674		
32	Bile Acid Malabsorption. 311-317		
31	Bioactive Peptides from Meat Proteins as Functional Food Components. 181-208		2
30	Implications for Farnesoid X Receptor Signaling on Bile Acid Metabolism as a Potential Therapeutic Strategy for Nonalcoholic Fatty Liver Disease. <i>The Korean Journal of Obesity</i> , 2016 , 25, 167-175		
29	Surgical management of diabetes mellitus: future outlook. <i>Endoscopic Surgery</i> , 2017 , 23, 46		0.2
28	Effect of Aqueous Warionia saharae Extract on Lipid and Glucose Metabolism in Normal and Diabetic Rats. <i>Natural Products Journal</i> , 2020 , 10, 605-610		0.6
27	. <i>Drug Metabolism and Disposition</i> , 2021 ,	4	5
26	Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering. <i>Foods</i> , 2021 , 10,	4.9	2
25	Investigate dysregulated lipid metabolism in diabetic mice via targeted metabolomics of bile acids in enterohepatic circulation.. <i>Rapid Communications in Mass Spectrometry</i> , 2021 , e9236		2.2
24	Integrative analysis of fecal metabolome and gut microbiota in high-fat diet-induced hyperlipidemic rats treated with Rosa Roxburghii Tratt juice. <i>Journal of Functional Foods</i> , 2022 , 90, 104978	5.1	2

23	Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives.. <i>Molecular Pharmaceutics</i> , 2022 ,	5.6	1
22	Dietary Intake of Hydrolyzable Tannins and Condensed Tannins to Regulate Lipid Metabolism.. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021 ,	3.2	0
21	Cholesterol transport in blood, lipoproteins, and cholesterol metabolism. 2022 , 227-258		
20	Effects of Fat Type and Exogenous Bile Acids on Growth Performance, Nutrient Digestibility, Lipid Metabolism and Breast Muscle Fatty Acid Composition in Broiler Chickens. <i>Animals</i> , 2022 , 12, 1258	3.1	1
19	Ion exchange biomaterials to capture daptomycin and prevent resistance evolution in off-target bacterial populations.		
18	Circulating Lipoproteins in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomy. <i>Nutrients</i> , 2022 , 14, 2381	6.7	0
17	Sorting Through the Extensive and Confusing Roles of Sortilin in Metabolic Disease. <i>Journal of Lipid Research</i> , 2022 , 100243	6.3	1
16	Bile acid metabolism and signaling, the microbiota, and metabolic disease. 2022 , 108238		1
15	Functional, Diagnostic and Therapeutic Aspects of Bile. <i>Clinical and Experimental Gastroenterology</i> , Volume 15, 105-120	3.1	1
14	Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans.		1
13	Hypolipidemic activity of the polysaccharide L-rhamnopyranosyl-6-O-methyl-galacturonan in combined administration with HMG-CoA reductase and cholesterol absorption inhibitors. 2022 , 11, 57-63		1
12	Effect of Coffee on the Bioavailability of Sterols. 2022 , 11, 2935		0
11	Ion Exchange Biomaterials to Capture Daptomycin and Prevent Resistance Evolution in Off-Target Bacterial Populations. 2022 , 14, 42864-42875		0
10	Sorption of bile salts from aqueous solutions by MCM-41 silica with chemically immobilized steroid groups.		0
9	A pilot reverse virtual screening study suggests toxic exposures caused long-term epigenetic changes in Gulf War Illness. 2022 , 20, 6206-6213		0
8	Bile acid-binding capacity of peptide extracts obtained from chicken blood hydrolysates using HPLC. 2022 , 114381		0
7	Bile acids and microbes in metabolic disease. 28, 6846-6866		0
6	Role of Renin Angiotensin System in the Pathophysiology of Coronary Heart Disease: Advancements in Diagnosis, Therapy and Preventive Strategies. 2023 , 211-235		0

- 5 Supplementation of *Weizmannia coagulans* BC2000 and Ellagic Acid Inhibits High-Fat-Induced Hypercholesterolemia by Promoting Liver Primary Bile Acid Biosynthesis and Intestinal Cholesterol Excretion in Mice. **2023**, 11, 264 ○
- 4 Correlates of Myopathy in Diabetic Patients Taking Statins. **2023**, ○
- 3 Effect of ultra-high pressure treatment on structural and functional properties of dietary fiber from pomelo fruitlets. **2023**, 52, 102436 ○
- 2 Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. **2023**, 24, 4019 ○
- 1 Effects of supplemental mixed bile acids on growth performance, body composition, digestive enzyme activities, skin color, and flesh quality of juvenile large yellow croaker (*Larimichthys crocea*) in soybean oil based diet. 10, ○